新辅助放化疗后手术时机选择对进展期直肠癌患者预后影响的研究进展

doi:10.3969/j.issn.1007-3969.2015.08.013

中国癌症杂志 ›› 2015, Vol. 25 ›› Issue (8): 635-640.doi: 10.3969/j.issn.1007-3969.2015.08.013

• 综述 • 上一篇

新辅助放化疗后手术时机选择对进展期直肠癌患者预后影响的研究进展

张　斌综述，汪　昱审校

上海交通大学附属第六人民医院普外科，上海 200233

出版日期:2015-08-30 发布日期:2015-12-14
通信作者: 汪昱　E-mail：wangyu11122@yahoo.cn

Study of impact of operation time interval after neoadjuvant chemoradiotherapy for locally progressed rectal patients’ outcome

ZHANG Bin, WANG Yu

Department of General Surgery, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China

Published:2015-08-30 Online:2015-12-14
Contact: WANG Yu E-mail: wangyu11122@yahoo.cn

摘要/Abstract

摘要： 进展期直肠癌行新辅助放化疗(neoadjuvant chemoradiotherapy，nCRT)后的延期手术可以增加根治切除机会，降低局部复发，同时改善患者总体生存率。常规的术前放化疗与手术之间的时间间隔为4~6周，延长手术时间间隔可以增加肿瘤退缩的程度，但是超过6~8周也可能会增加手术难度、手术并发症发生率及肿瘤复发或转移的风险。回顾分析相关文献，从肿瘤缓解率、预后、患病率和死亡率等方面对nCRT后延期手术时机选择对预后影响的研究进展进行综述。

关键词: 新辅助治疗, 手术时机, 局部进展期直肠癌

Abstract: Neoadjuvant chemoradiotherapy (nCRT) is used to downstage locally advanced rectal cancer before surgery, in order to increase the chance of radical resection, reduce local recurrence, and improve overall survival. Accumulating data suggest that tumor response to nCRT is time dependent. A delay between nCRT and surgery may increase the proportion of patients that achieve a favorable response, and 4-6 weeks are considered to be a universal interval. However, delayed surgery beyond 6-8 weeks may increase the technical difficulty, and the risks of surgical complications and recurrence or metastasis. This article briefly reviews the relevant literature to evaluate the efficiency and safety of delayed surgery.

Key words: Neoadjuvant chemoradiotherapy, Operation time interval, Locally progressed rectal carcinoma

张　斌,汪　昱. 新辅助放化疗后手术时机选择对进展期直肠癌患者预后影响的研究进展[J]. 中国癌症杂志, 2015, 25(8): 635-640.

ZHANG Bin, WANG Yu. Study of impact of operation time interval after neoadjuvant chemoradiotherapy for locally progressed rectal patients’ outcome[J]. China Oncology, 2015, 25(8): 635-640.

[1]	《中国乳腺癌新辅助治疗专家共识（2022年版）》专家组. 中国乳腺癌新辅助治疗专家共识（2022年版）[J]. 中国癌症杂志, 2022, 32(1): 80-89.
[2]	毕　钊, 宋现让, 陈　鹏, 谢　丽, 蒋　伟, 宋兴国, 丛斌斌, 王永胜 . 中性粒细胞与淋巴细胞比值预测乳腺癌新辅助治疗后腋窝淋巴结病理学完全缓解的研究[J]. 中国癌症杂志, 2021, 31(1): 63-68.
[3]	中国乳腺癌新辅助治疗专家组. 中国乳腺癌新辅助治疗专家共识（2019年版）[J]. 中国癌症杂志, 2019, 29(5): 390-400.
[4]	毛　艳，王海波. 乳腺癌新辅助治疗过程中手术时机的选择[J]. 中国癌症杂志, 2019, 29(10): 761-766.
[5]	中国抗癌协会大肠癌专业委员会. 中国局部进展期直肠癌诊疗专家共识[J]. 中国癌症杂志, 2017, 27(1): 41-80.

新辅助放化疗后手术时机选择对进展期直肠癌患者预后影响的研究进展

Study of impact of operation time interval after neoadjuvant chemoradiotherapy for locally progressed rectal patients’ outcome

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

本文评价